Levosimendan Injection 12.5 mg

Generic Equivalent of Simdax®

Advanced Inotropic Support for Acute Heart Failure and Low Cardiac Output Conditions

Last Updated: June 17, 2026

Medical Review Status: Reviewed for scientific and regulatory accuracy

Reviewed By: Pharmaceutical Affairs Team

Review Date: June 17, 2026

Reading Time: 4 min read

Product Overview

Levosimendan Injection 12.5 mg is an advanced cardiovascular therapy used for the short-term treatment of acute decompensated heart failure (ADHF) and low cardiac output conditions requiring additional hemodynamic support. As a generic equivalent of Simdax®, Levosimendan offers a unique mechanism of action that improves cardiac contractility while promoting vasodilation, helping optimize cardiovascular performance in critically ill patients managed in hospitals, intensive care units, and specialized cardiac care settings.

Heart failure remains one of the leading causes of hospitalization and healthcare burden worldwide, creating an ongoing demand for innovative therapies capable of improving cardiac function while minimizing additional myocardial stress. Levosimendan Injection is recognized for its calcium-sensitizing properties, which enhance myocardial contractility without significantly increasing intracellular calcium concentrations or myocardial oxygen consumption. This unique pharmacological profile differentiates Levosimendan from conventional inotropic therapies and supports its use in modern cardiovascular management strategies.

Healthcare providers, cardiologists, critical care specialists, and hospital procurement teams continue to seek reliable access to high-quality Levosimendan Injection for the management of acute heart failure, perioperative cardiac dysfunction, and low cardiac output syndrome. As a trusted Levosimendan manufacturer and supplier, we support pharmaceutical distributors, healthcare institutions, government procurement agencies, and international partners with dependable access to this essential cardiovascular medicine.

Manufactured in cGMP-compliant facilities and supported by comprehensive quality assurance systems, our Levosimendan Injection 12.5 mg is available for hospital procurement programs, pharmaceutical distribution networks, government tenders, institutional healthcare supply, and global export markets. We provide regulatory documentation, supply chain reliability, and commercial flexibility to support customers across the United States, United Kingdom, Europe, GCC countries, Africa, Southeast Asia, and other international healthcare markets.

Key Product Information

Generic Name: Levosimendan Injection

Brand Reference: Simdax®

Strength: 12.5 mg

Therapeutic Class: Inodilator / Calcium Sensitizer

Dosage Form: Concentrate for Solution for Infusion

Route of Administration: Intravenous Infusion

Prescription Status: Prescription Only Medicine (Rx)

Storage Conditions: Refer to approved product labeling

Manufacturer: Available Upon Request

Supply Markets: USA, UK, Europe, GCC, Africa, Asia-Pacific, Latin America

Key Benefits

Improves Cardiac Contractility

Levosimendan enhances myocardial performance through calcium sensitization, helping improve cardiac output and circulatory function.

Dual Mechanism of Action

Combines positive inotropic effects with vasodilatory activity, providing comprehensive cardiovascular support.

Supports Hemodynamic Stability

Helps optimize cardiac performance in patients requiring short-term circulatory support and advanced heart failure management.

Reduced Impact on Myocardial Oxygen Demand

Improves cardiac function without substantially increasing myocardial oxygen consumption compared to certain traditional inotropic therapies.

Trusted Hospital Therapy

Widely utilized in cardiology departments, intensive care units, and perioperative cardiac care settings.

Mechanism of Action

Levosimendan acts as a calcium sensitizer by binding to cardiac troponin C in a calcium-dependent manner, enhancing myocardial contractility without significantly increasing intracellular calcium levels.

In addition, Levosimendan activates ATP-sensitive potassium channels in vascular smooth muscle, resulting in vasodilation and reduced preload and afterload. This dual mechanism contributes to improved cardiac output, enhanced tissue perfusion, and overall hemodynamic support.

Potential Clinical Applications

Subject to local regulatory approvals, prescribing information, and clinical judgment, Levosimendan Injection 12.5 mg may be considered in the management of:

• Acute Decompensated Heart Failure (ADHF)
• Low Cardiac Output Syndrome
• Advanced Heart Failure Requiring Inotropic Support
• Perioperative Cardiac Dysfunction
• Cardiac Surgery-Associated Hemodynamic Instability
• Intensive Care Cardiovascular Support
• Selected Cases of Cardiogenic Shock

Treatment decisions should be based on patient-specific assessment, clinical guidelines, and approved prescribing information.

Target Disease Areas

Levosimendan Injection is commonly utilized in specialized cardiovascular care environments involving:

• Acute Heart Failure
• Advanced Heart Failure
• Low Cardiac Output Conditions
• Hemodynamic Instability
• Cardiogenic Shock
• Perioperative Cardiac Dysfunction
• Critical Care Cardiovascular Conditions

Why Choose Us

Healthcare providers, procurement agencies, and pharmaceutical distributors choose us for our commitment to quality, regulatory compliance, and reliable global supply.

Our Strengths

• cGMP-Compliant Manufacturing Facilities
• International Quality Standards
• Reliable Global Supply Chain
• Regulatory Documentation Support
• Government Tender Supply Experience
• Pharmaceutical Distribution Expertise
• Competitive Commercial Solutions
• Dedicated Customer Support

Documentation Available

Comprehensive documentation may be available to support registration, procurement, and regulatory requirements.

• Certificate of Analysis (COA)
• Certificate of Pharmaceutical Product (COPP)
• GMP Certificates
• Product Specifications
• Stability Data
• CTD / ACTD Dossiers
• Batch Documentation
• Regulatory Support Documents

Documentation availability may vary according to market-specific requirements.

Packaging Information

Levosimendan Injection 12.5 mg is available in hospital and institutional packaging configurations suitable for cardiology departments, intensive care units, and specialized healthcare facilities.

Customized packaging options may be available based on customer requirements and local regulatory guidelines.

Global Supply Capabilities

We support pharmaceutical distributors, healthcare institutions, procurement agencies, government organizations, and hospital networks across:

• United States
• United Kingdom
• European Union
• GCC Countries
• Africa
• Southeast Asia
• Latin America
• International Export Markets

Frequently Asked Questions

What is Levosimendan Injection 12.5 mg?

Levosimendan Injection is an advanced inodilator therapy used to provide short-term hemodynamic support in patients with acute heart failure and low cardiac output conditions.

Is Levosimendan Injection the Generic Equivalent of Simdax®?

Yes. Levosimendan Injection is developed as a generic equivalent of Simdax®.

How does Levosimendan work?

Levosimendan improves myocardial contractility through calcium sensitization while promoting vasodilation through activation of ATP-sensitive potassium channels.

What are the clinical uses of Levosimendan Injection?

It may be considered for acute decompensated heart failure, low cardiac output syndrome, perioperative cardiac dysfunction, and selected cardiovascular critical care situations.

Is this product available for hospital procurement?

Yes. Levosimendan Injection is available for hospital procurement programs, pharmaceutical distribution networks, and institutional healthcare supply.

Is regulatory documentation available?

Comprehensive regulatory and quality documentation may be available to support product registration and procurement requirements.

Do you support international distribution?

Yes. We support pharmaceutical distributors, healthcare organizations, government procurement agencies, and international partners across multiple global markets.

References

1. International Heart Failure Management Guidelines.
2. European Medicines Agency (EMA) Scientific Publications.
3. Published Clinical Studies on Levosimendan.
4. Peer-Reviewed Cardiovascular Medicine Literature.
5. Global Cardiovascular Care and Critical Care Guidelines.

Medical Disclaimer

This information is intended for healthcare professionals, pharmaceutical distributors, procurement specialists, regulatory stakeholders, and institutional buyers. It is provided for informational purposes only and should not be considered medical advice, diagnosis, or treatment guidance.

Prescribing decisions should be based on approved product labeling, local regulatory requirements, clinical judgment, and individual patient needs. Always consult qualified healthcare professionals and official prescribing information before use.

Request Product Information

For pricing inquiries, regulatory documentation, hospital procurement requirements, distribution opportunities, bulk supply requests, contract manufacturing discussions, or partnership opportunities regarding Levosimendan Injection 12.5 mg (Generic Simdax®), please contact our pharmaceutical business development team.